Bhalchandra Kawdikar: FDA Approves Rusfertide for Polycythemia Vera
Bhalchandra Kawdikar, Vice President International Marketing at Edge Pharma (merchant Exporter), shared a post on LinkedIn:
”FDA Approves MIMRYLO Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera Aug 28, 2026.
Why it matters: New hope in reducing the risk of life-threatening conditions due to chronic blood cancer.
PV is a chronic blood cancer. In PV RBC’s are overproduced, increasing the blood viscosity.
This can result in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism.
Takeda’s Mimrylo (Rusfertide) is a first-in-class SC Inj. It mimics the action of hepcidin, (a natural hormone that regulates iron homeostasis and erythrocytosis).
By targeting the underlying mechanism of iron dysregulation MIMRYLO aims reduces excess RBC production and helps maintain hematocrit control.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke